Boehringer Ingelheim Launches the First-Ever Registered Stem Cell-Based Veterinary Medicine
European Commission has granted marketing authorisation for the first stem cell-based product in animal health
Arti-Cell® Forte is a unique ready-to-use solution for the treatment of equine lameness
The partnership of Boehringer Ingelheim and GST proves its commitment to bring highly innovative therapeutics for horses to customers
April 09, 2019 17:25 KST
INGELHEIM, GERMANY--(Business Wire / Korea Newswire) April 09, 2019 -- Boehringer Ingelheim launches Arti-Cell® Forte in Europe for the ‘reduction of mild to moderate recurrent lameness associated with non-septic joint inflammation in horses’.
Equine lameness is truly common and impacts horse performance as well as equine welfare. Current treatment is not satisfactory for all cases and there is a clear need for innovation and new treatment options. Hence, the significant interest in treatment beyond symptoms, namely combatting the underlying root cause.
Arti-Cell® Forte is a groundbreaking first-ever approved therapy, developed towards targeting lameness, utilising specifically primed, chondrogenic induced stem cells. Arti-Cell® Forte comes in an ultra-low frozen ready-to-use presentation.
Boehringer Ingelheim and Global Stem cell Technology (GST), that formed a partnership last year, have the same ambition to bring new treatments and solutions to improve animal health; therefore, Arti-Cell® Forte was specifically designed for horses to provide a convenient and long-term solution for recurrent lameness.
“A quarter of the entire equine population develops osteoarthritis at some point in their life. Priming the cells towards cartilage aids them to deliver the right activities in the affected joint,” says Jan Spaas, CEO of GST. “We are absolutely delighted with our first marketing authorisation from the European Commission and the first stem cell-based product in Animal Health. We are sure that with our partner Boehringer Ingelheim this product will become a game changer in equine health.”
Dr. Erich Schoett, Head of the Global Strategic Business Unit Equine at Boehringer Ingelheim, shares: “We are proud to continue to set new standards of care for horses to optimise their health and well-being in partnership with veterinarians. Early disease detection and early treatment are key to ensure that horses are healthy and live longer, happier lives. Arti-Cell® Forte as the first-ever approved stem cell-based product offers to veterinarians and horse owners a ready-to-use solution to help raising the health and quality of life for horses with mild to moderate recurrent lameness”.
Following the scientific review by the European Medicines Agency and decision of EU marketing authorisation by the European Commission, Arti-Cell® Forte is now approved as a veterinary medicine for the treatment of equine lameness. It will be available from May and June 2019 onwards in a range of European Countries.
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
Please click on the link for ‘Notes to Editors’ and ‘References’:
View source version on businesswire.com: https://www.businesswire.com/news/home/20190409005445/en/
Animal Health Communication
+49 170 9388827
- Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors
- Boehringer Ingelheim and University of Dundee Highlight Successful PROTAC Drug Discovery Program and Extend Their Ongoing Anti-Cancer Alliance
- Full data from CAROLINA® outcome trial support long-term cardiovascular safety profile of Trajenta®
- New post-hoc analysis shows consistent cardiorenal risk reductions of empagliflozin in a sub-group of adults with type 2 diabetes and chronic kidney disease without overt proteinuria
- Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists
Share this News Release
Animal Health Communication
+49 170 9388827